(Q40359188)

19 September 2017

title

Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates (English)

1 reference

19 September 2017

10

1 reference

19 September 2017

3

David C Montefiori

1 reference

19 September 2017

1

Barton F Haynes

1 reference

19 September 2017

Christos J Petropoulos

series ordinal

5

object named as

Christos J Petropoulos

1 reference

19 September 2017

11

Hua-Xin Liao

1 reference

19 September 2017

6

Laura L Sutherland

1 reference

19 September 2017

7

Richard M Scearce

1 reference

19 September 2017

4

Terri Wrin

1 reference

19 September 2017

9

Shi-Mao Xia

1 reference

19 September 2017

Benjiang Ma

2

1 reference

19 September 2017

Cathrine Denton

series ordinal

8

1 reference

19 September 2017

language of work or name

English

0 references

publication date

20 October 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

345

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

44-55

1 reference

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Structure and polymorphism of HIV-1 third variable loops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Measuring vaccine-induced HIV neutralization: report of a workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Performance evaluation of amino acid substitution matrices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

inferred from DOI database lookup

7 January 2021

based on heuristic

Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

inferred from DOI database lookup

7 January 2021

based on heuristic

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.08.042

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.08.042

1 reference

19 September 2017

1 reference